|
KMID : 1141720170050020004
|
|
폐쇄성폐질환
2017 Volume.5 No. 2 p.4 ~ p.4
|
|
|
|
|
Hur Gyu-Young
|
|
|
Abstract
|
|
|
|
Asthma is a heterogeneous disease with complex pathological mechanisms. Currently, asthma treatment is based on inhaled corticosteroid (ICS) and long-acting β2 agonists (LABA), but some asthmatics have poor response to high dose ICS treatment. Several new treatments have been approved for severe asthma. Tiotropium has been approved as an additional therapeutic option despite of high dose ICS and/or LABA treatment. Bronchial thermoplasty has also a suggested therapy in severe asthma. New humanized antibodies to Th2 targets, including IgE, IL-4, IL-5, and IL-13 antibodies, have revealed promising results in some asthmatics. To identify appropriate patients for newer treatment, specific biomarkers including sputum and/or blood eosinophilia can be used. They can be used to predict the outcome of clinical and inflammatory responses. Therefore, distinguishing specific phenotypes of asthma patients using various inflammatory biomarkers may be a prerequisite for selecting appropriate treatment modalities for severe asthma.
|
|
|
KEYWORD
|
|
|
Severe asthma, Asthma phenotype, Biologic treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|